CRVS
Corvus Pharmaceuticals, Inc.
Biotechnology
Market Cap$1.23B
5Y Perf.+322.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CRVS vs ALEC
Revenue, margins, valuation, and 5-year total return — side by side.
ALEC
Alector, Inc.
Biotechnology
Market Cap$269M
5Y Perf.-92.5%
CRVS vs ALEC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CRVS | ALEC |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.23B | $269M |
| Revenue (TTM) | $0.00 | $21M |
| Net Income (TTM) | $-44M | $-143M |
| Operating Margin | — | -7.4% |
| Total Debt | $937K | $36M |
| Cash & Equiv. | $5M | $66M |
CRVS vs ALEC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CRVS
ALEC
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Corvus Pharmaceutic… (CRVS) | 100 | 422.9 | +322.9% |
| Alector, Inc. (ALEC) | 100 | 7.5 | -92.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CRVS vs ALEC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CRVS leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
CRVS
Corvus Pharmaceuticals, Inc.
The Income Pick
CRVS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.63
- EPS growth 48.0%
- 17.1% 10Y total return vs ALEC's -86.4%
Best for: income & stability and growth exposure
ALEC
Alector, Inc.
The Specific-Use Pick
In this particular matchup, ALEC is outpaced on most metrics by others in the set.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CRVS | -6.6% revenue growth vs ALEC's -79.1% |
| Quality / Margins | CRVS | 3.5% margin vs ALEC's -6.8% |
| Stability / Safety | CRVS | Beta 1.63 vs ALEC's 2.47, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CRVS | +355.9% vs ALEC's +139.2% |
| Efficiency (ROA) | CRVS | -35.7% ROA vs ALEC's -48.7%, ROIC -78.1% vs -170.3% |
CRVS vs ALEC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2021
CRVS vs ALEC — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCRVSLAGGINGALEC
ALECAlector, Inc.
0leads
CRVSCorvus Pharmaceutical…
3leads
6 Total Categories
CATEGORYLEADERvs ALECMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CRVS1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CRVS6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
CRVS6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CRVS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ALEC and CRVS operate at a comparable scale, with $21M and $0 in trailing revenue.
| Metric | CRVSCorvus Pharmaceut… | ALECAlector, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $21M |
| EBITDAEarnings before interest/tax | -$48M | -$156M |
| Net IncomeAfter-tax profit | -$44M | -$143M |
| Free Cash FlowCash after capex | -$35M | -$184M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | -7.4% |
| Net MarginNet income ÷ Revenue | — | -6.8% |
| FCF MarginFCF ÷ Revenue | — | -8.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -88.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -15.4% | -15.1% |
CRVS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — CRVS and ALEC each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | CRVSCorvus Pharmaceut… | ALECAlector, Inc. |
|---|---|---|
| Market CapShares × price | $1.2B | $269M |
| Enterprise ValueMkt cap + debt − cash | $1.2B | $240M |
| Trailing P/EPrice ÷ TTM EPS | -27.53x | -1.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 12.80x |
| Price / BookPrice ÷ Book value/share | 19.01x | 8.20x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — CRVS and ALEC each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
CRVS leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
CRVS delivers a -38.9% return on equity — every $100 of shareholder capital generates $-39 in annual profit, vs $-5 for ALEC. CRVS carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ALEC's 1.18x. On the Piotroski fundamental quality scale (0–9), CRVS scores 3/9 vs ALEC's 1/9, reflecting mixed financial health.
| Metric | CRVSCorvus Pharmaceut… | ALECAlector, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -38.9% | -4.7% |
| ROA (TTM)Return on assets | -35.7% | -48.7% |
| ROICReturn on invested capital | -78.1% | -170.3% |
| ROCEReturn on capital employed | -90.2% | -55.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 1 |
| Debt / EquityFinancial leverage | 0.02x | 1.18x |
| Net DebtTotal debt minus cash | -$4M | -$30M |
| Cash & Equiv.Liquid assets | $5M | $66M |
| Total DebtShort + long-term debt | $937,000 | $36M |
| Interest CoverageEBIT ÷ Interest expense | -18.29x | — |
CRVS leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
CRVS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CRVS five years ago would be worth $50,137 today (with dividends reinvested), compared to $1,492 for ALEC. Over the past 12 months, CRVS leads with a +355.9% total return vs ALEC's +139.2%. The 3-year compound annual growth rate (CAGR) favors CRVS at 123.9% vs ALEC's -32.5% — a key indicator of consistent wealth creation.
| Metric | CRVSCorvus Pharmaceut… | ALECAlector, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +99.3% | +59.5% |
| 1-Year ReturnPast 12 months | +355.9% | +139.2% |
| 3-Year ReturnCumulative with dividends | +1022.3% | -69.2% |
| 5-Year ReturnCumulative with dividends | +401.4% | -85.1% |
| 10-Year ReturnCumulative with dividends | +17.1% | -86.4% |
| CAGR (3Y)Annualised 3-year return | +123.9% | -32.5% |
CRVS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CRVS and ALEC each lead in 1 of 2 comparable metrics.
Risk & Volatility
CRVS is the less volatile stock with a 1.63 beta — it tends to amplify market swings less than ALEC's 2.47 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALEC currently trades 71.8% from its 52-week high vs CRVS's 54.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CRVSCorvus Pharmaceut… | ALECAlector, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.63x | 2.47x |
| 52-Week HighHighest price in past year | $26.95 | $3.40 |
| 52-Week LowLowest price in past year | $3.17 | $0.97 |
| % of 52W HighCurrent price vs 52-week peak | +54.1% | +71.8% |
| RSI (14)Momentum oscillator 0–100 | 49.2 | 59.1 |
| Avg Volume (50D)Average daily shares traded | 1.2M | 684K |
Evenly matched — CRVS and ALEC each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CRVS as "Buy" and ALEC as "Buy". Consensus price targets imply 127.3% upside for CRVS (target: $33) vs 43.4% for ALEC (target: $4).
| Metric | CRVSCorvus Pharmaceut… | ALECAlector, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $33.17 | $3.50 |
| # AnalystsCovering analysts | 13 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CRVS leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallCorvus Pharmaceuticals, Inc. (CRVS)Leads 3 of 6 categories
Loading custom metrics...
CRVS vs ALEC: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CRVS or ALEC a better buy right now?
Analysts rate Corvus Pharmaceuticals, Inc.
(CRVS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CRVS or ALEC?
Over the past 5 years, Corvus Pharmaceuticals, Inc.
(CRVS) delivered a total return of +401. 4%, compared to -85. 1% for Alector, Inc. (ALEC). Over 10 years, the gap is even starker: CRVS returned +17. 1% versus ALEC's -86. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CRVS or ALEC?
By beta (market sensitivity over 5 years), Corvus Pharmaceuticals, Inc.
(CRVS) is the lower-risk stock at 1. 63β versus Alector, Inc. 's 2. 47β — meaning ALEC is approximately 51% more volatile than CRVS relative to the S&P 500. On balance sheet safety, Corvus Pharmaceuticals, Inc. (CRVS) carries a lower debt/equity ratio of 2% versus 118% for Alector, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — CRVS or ALEC?
On earnings-per-share growth, the picture is similar: Corvus Pharmaceuticals, Inc.
grew EPS 48. 0% year-over-year, compared to -13. 0% for Alector, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CRVS or ALEC?
Corvus Pharmaceuticals, Inc.
(CRVS) is the more profitable company, earning 0. 0% net margin versus -679. 2% for Alector, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRVS leads at 0. 0% versus -741. 3% for ALEC. At the gross margin level — before operating expenses — CRVS leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CRVS or ALEC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CRVS or ALEC better for a retirement portfolio?
For long-horizon retirement investors, Corvus Pharmaceuticals, Inc.
(CRVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Alector, Inc. (ALEC) carries a higher beta of 2. 47 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRVS: +17. 1%, ALEC: -86. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CRVS and ALEC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.